AXIL - Rasio utang marang kapitalisasi buku reviveprocare.com

Logo grafis AXIL Brands (AXIL)

Cosmetics manufacturer AXIL Brands, Inc. (AXIL) adheres to a clean beauty and recyclable packaging concept, which is supported by this GURU.Markets chart on the share of debt obligations in balance sheet capital; meanwhile, 0.03 shows the current value of this metric. Management is effectively expanding premium accessories via marketplaces, while moderate pricing power allows the company to offset inflation despite aggressive discounting in the mass market.

AXIL (AXIL Brands) riwayat Utang marang nilai buku saka 21.02.2024 nganti 27.10.2026

reviveprocare.com (AXIL) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham AXIL Brands|AXIL - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar Revive Pro Care|AXIL - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham AXIL Brands|AXIL - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku reviveprocare.com|AXIL - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas AXIL Brands, Inc.|AXIL - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas AXIL Brands|AXIL - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Revive Pro Care
Ringkesan analitik perusahaan:Revive Pro Care AXIL
Barang utama AXIL Brands

A conservative investor assesses the stability of AXIL Brands, Inc. (AXIL) through the lens of its debt load. For this hearing protection systems manufacturer, the balance of borrowed capital is critical when expanding into B2B and B2C segments. Analyzing this chart of the debt-to-equity structure, we see the ratio of total liabilities to the value of assets minus liabilities. A decrease in this coefficient minimizes default risk, while an increase indicates aggressive scaling of market share. A stable trend confirms the financial reliability of the issuer.

Pesaing AXIL Brands, Inc.

Utang-utang marang kapitalisasi buku KRYS (Krystal Biotech, Inc.)|apogeetherapeutics.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Arcutis Biotherapeutics, Inc. (ARQT)|VCEL: Rasio utang marang aset resik|ORKA (Oruka Corp) - Rasio utang marang kapitalisasi buku|Sanara MedTech (SMTI) - Utang marang nilai buku|DBVT (DBV Tech) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Solesence Inc. (SLSN)|Journey Medical (DERM) - Utang marang nilai buku|Rasio utang marang aset resik FBRX (Forte Biosciences Inc.)|Rasio utang marang kapitalisasi buku EMPG|Sol-Gel Technologies, Ltd. - Utang-utang marang aset resik|Medicus Pharma Ltd. - Rasio utang marang kapitalisasi buku|VRCA - Utang-utang marang kapitalisasi buku|hoththerapeutics.com - Utang-utang marang kapitalisasi buku|BFRI (Biofrontera) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku VYNE Therapeutics, Inc. (VYNE)|Rasio utang marang nilai buku Sonoma Pharma|Utang-utang marang kapitalisasi buku QNRX|Utang-utang marang kapitalisasi buku azitrainc.com AZTR|DRMA - Utang marang nilai buku|Rasio utang marang nilai buku Elevai Labs Inc ELAB|Utang-utang marang kapitalisasi buku RVNC (Revance Therapeutics, Inc)